Abstract
I read with great interest “A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization” by Hess et al1 published on June 20, 2017. Cilostazol has been cited in the Antithrombotic Therapy After Endovascular Peripheral Revascularization section, where it was reported to significantly improve vascular patency at 36 months after peripheral endovascular interventions in a single randomized trial including 127 patients with femoropopliteal disease undergoing endovascular intervention randomized to cilostazol plus aspirin versus aspirin alone (odds ratio, 0.40; 95% confidence interval, 0.19–0.83).2 In the aforementioned section, some points deserve clarification and integration. First, the study did not randomize patients …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
